Visser Lance C, Kaplan Joanna L, Nishimura Satoko, Gunther-Harrington Catherine T, Bélanger Catherine, Oldach Maureen S, Stern Joshua A, Mueller Mikaela S
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California.
J Vet Intern Med. 2018 Jul;32(4):1299-1307. doi: 10.1111/jvim.15224. Epub 2018 Jul 3.
Sotalol is a commonly used antiarrhythmic drug that may alter ventricular function.
To determine the effect of sotalol on echocardiographic indices of ventricular systolic function in dogs with ventricular arrhythmias.
Thirty-five client-owned dogs with ventricular arrhythmias.
Dogs with ventricular arrhythmias (n = 27) had an echocardiogram and 5-minute ECG performed at baseline and 2-4 hours post-sotalol (2-2.5 mg/kg PO once). Eight additional dogs underwent the same protocol but did not receive sotalol (within-day variability controls). Left ventricular (LV) internal dimension at end-systole normalized to bodyweight (LVIDs_N), LV ejection fraction (LV EF), LV shortening area, LV fractional shortening, tricuspid annular plane systolic excursion (TAPSE), and right ventricular systolic myocardial velocity were evaluated as indices of systolic function.
All indices except TAPSE had mild decreases in systolic function post-sotalol (all P ≤ .0007) compared with baseline but only the percent change in LVIDs_N and LV EF were significantly (P ≤ .0079) different from the percent change of the same indices in control dogs. Sinus heart rate, ventricular premature complexes/5-minutes, and arrhythmia grade also were decreased post-sotalol (all P ≤ .01) compared with baseline when assessed by a 5-minutes ECG. No dog experienced an adverse event post-sotalol, including dogs with systolic dysfunction or atrial enlargement.
A single dose of sotalol may cause a mild decrease in LV systolic function in dogs with ventricular arrhythmias. Sotalol appears to be well tolerated, even in dogs with atrial enlargement or systolic dysfunction.
索他洛尔是一种常用的抗心律失常药物，可能会改变心室功能。
确定索他洛尔对患有室性心律失常犬的心室收缩功能超声心动图指标的影响。
35只客户拥有的患有室性心律失常的犬。
患有室性心律失常的犬（n = 27）在基线时以及索他洛尔给药后2 - 4小时（口服2 - 2.5 mg/kg，一次）进行超声心动图检查和5分钟心电图检查。另外8只犬接受相同方案但未接受索他洛尔（日内变异性对照）。评估左心室（LV）收缩末期内径与体重的比值（LVIDs_N）、左心室射血分数（LV EF）、左心室缩短面积、左心室缩短分数、三尖瓣环平面收缩期位移（TAPSE）以及右心室收缩期心肌速度作为收缩功能指标。
与基线相比，除TAPSE外，所有指标在索他洛尔给药后收缩功能均有轻度下降（所有P≤0.0007），但只有LVIDs_N和LV EF的变化百分比与对照犬相同指标的变化百分比有显著差异（P≤0.0079）。通过5分钟心电图评估，与基线相比，索他洛尔给药后窦性心率、室性早搏/5分钟以及心律失常分级也有所下降（所有P≤0.01）。没有犬在索他洛尔给药后出现不良事件，包括患有收缩功能障碍或心房增大的犬。
单剂量索他洛尔可能会使患有室性心律失常的犬左心室收缩功能轻度下降。索他洛尔似乎耐受性良好，即使在患有心房增大或收缩功能障碍的犬中也是如此。
